6 companies are listed as peptide manufacturers and suppliers in Germany. 2 hold active US Drug Master Files for peptide APIs, most often for Linaclotide, Teriparatide. 2 have a regulator record of GMP manufacturing. 4 score High (90 or more).
Ordered by score. Scores follow the published rules and are not affected by paid placement. Updated 2026-11-13.
Hamburg microbial biologics CDMO founded 1987, now wholly owned by Gedeon Richter; FDA-inspected 2013, 2018 and 2026; US DMF for teriparatide.
European CDMO network with a dedicated peptide, lipid and carbohydrate platform.
German peptide maker founded in 2001 near Berlin, selling catalogue peptides and peptide pools and offering custom synthesis on in-house built synthesis robots.
Heidelberg company founded in 2000 that synthesizes custom peptides and produces specific antibodies from the Heidelberg Technology Park.
Tübingen peptide company with about 30 years in peptide synthesis, making custom peptides, libraries, arrays, PNAs and neoantigen vaccine peptides.
Berlin peptide maker offering custom synthesis, peptide catalogues, peptide pools, microarrays and pre-GMP peptides, with a TÜV Rheinland-certified ISO 9001 system.
6 companies. Each listing shows location, business model, documentation and a score from 0 to 100.
By score: Richter-Helm BioTec GmbH & Co. KG (Richter BioLogics) (98), CordenPharma (90), peptides & elephants GmbH (90), PSL Peptide Specialty Laboratories GmbH (90), Intavis Peptide Services GmbH (75). Scores measure checkable evidence, not product quality, and paid placement does not change them.
Richter-Helm BioTec GmbH & Co. KG (Richter BioLogics) and CordenPharma hold active Type II DMFs for peptide APIs in FDA's DMF list. A DMF is a confidential file submitted to FDA; FDA does not approve DMFs, but drug applications can reference them.
Confirm the legal entity, ask for lot-specific certificates of analysis that the testing lab can verify, check FDA warning letters and import alerts, and for GMP material ask for regulator inspection records rather than marketing claims.